You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

Details for Patent: 9,833,448


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,833,448 protect, and when does it expire?

Patent 9,833,448 protects UBRELVY and is included in one NDA.

This patent has sixty-four patent family members in forty-three countries.

Summary for Patent: 9,833,448
Title:Piperidinone carboxamide azaindane CGRP receptor antagonists
Abstract: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Inventor(s): Bell; Ian M. (Harleysville, PA), Fraley; Mark E. (North Wales, PA), Gallicchio; Steven N. (Horsham, PA), Ginnetti; Anthony (Perkasie, PA), Mitchell; Helen J. (Richboro, PA), Paone; Daniel V. (Lansdale, PA), Staas; Donnette D. (Harleysville, PA), Wang; Cheng (Fort Washington, PA), Zartman; C. Blair (Hatfield, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:15/293,569
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,833,448

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS ⤷  Try a Trial
Abbvie UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,833,448

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083831 ⤷  Try a Trial
Australia 2011326454 ⤷  Try a Trial
Brazil 112013011448 ⤷  Try a Trial
Canada 2817100 ⤷  Try a Trial
Chile 2013001289 ⤷  Try a Trial
China 103328478 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.